The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: A randomised, double-blind, placebo-controlled trial

BMJ Open

Volumn 5, Issue 1, 2015, Pages

  Viasus, Diego ^a,b   Garcia Vidal, Carolina ^b   Simonetti, Antonella F ^b   Dorca, Jordi ^b,c   Llopis, Ferran ^b,c   Mestre, Mariona ^b   Morandeira Rego, Francisco ^b   Carratalà, Jordi ^b  

^a UNIVERSIDAD DEL NORTE   (Colombia)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; INTERLEUKIN 10; INTERLEUKIN 6; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXYGEN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL OXYGEN SATURATION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; AGED; ANALYSIS OF VARIANCE; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; LENGTH OF STAY; MIDDLE AGED; PNEUMONIA; PRESSURE; PROSPECTIVE STUDY; SPAIN; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LENGTH OF STAY; MALE; MIDDLE AGED; OXYGEN; PARTIAL PRESSURE; PNEUMONIA; PROSPECTIVE STUDIES; SIMVASTATIN; SPAIN;

EID: 84920742364     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006251     Document Type: Article

References (22)

1. Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
2. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
3. Rosón B, Carratalà J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001;33:158-65.
4. Rodriguez A, Lisboa T, Blot S, et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009;35:430-8.
5. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-7.
6. Menéndez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009;64:987-92.
7. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis. Arch Intern Med 2007;167:1655-63.
8. Fernández-Serrano S, Dorca J, Coromines M, et al. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003;10:813-20.
9. Viasus D, Garcia-Vidal C, Gudiol F, et al. Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis 2010;29:143-52.
10. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-7.
11. Thomsen RW, Riis A, Kornum JB, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008;168:2081-7.
12. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008;31:611-7.
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
14. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999.
15. Kruger P, Bailey M, Bellomo R, et al.; The ANZ-STATInS Investigators-ANZICS Clinical Trials Group. A multicentre randomised trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013;187:743-50.
16. Kruger PS, Harward ML, Jones MA, et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011;183:774-81.
17. Novack V, Eisinger M, Frenkel A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009;35:1255-60.
18. Patel JM, Snaith C, Thickett DR, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012;16:R231.
19. Truwit JD, Bernard GR, Steingrub J, et al. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014;370:2191-200.
20. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112:117-24.
21. Gogos C, Kotsaki A, Pelekanou A, et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 2010;14:R96.
22. Rowan C, Brinker AD, Nourjah P, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009;18:301-9.